Ratings MEI Pharma, Inc. Deutsche Boerse AG

Equities

MMI0

US55279B3015

Delayed Deutsche Boerse AG Other stock markets 02:13:00 2023-04-18 EDT			5-day change	1st Jan Change
4.2 ^EUR	-17.32%		-.--%	-.--%

05-09	MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
04-11	MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Over the last twelve months, the sales forecast has been frequently revised upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's earnings growth outlook lacks momentum and is a weakness.
The company has insufficient levels of profitability.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MEI PHARMA, INC.	-.--%	19.06M	-
MODERNA, INC.	+38.36%	52.73B	B-
LONZA GROUP AG	+39.33%	39B	A
IQVIA HOLDINGS INC.	-8.63%	38.52B	B
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	30.38B	B
CELLTRION, INC.	-11.17%	26.39B	C
ICON PUBLIC LIMITED COMPANY	+11.44%	26.08B	B-
UNITED THERAPEUTICS CORPORATION	+45.09%	14.15B	B+
MEDPACE HOLDINGS, INC.	+32.93%	12.6B	C+
BIO-TECHNE CORPORATION	-5.30%	11.51B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes